<DOC>
	<DOCNO>NCT00317681</DOCNO>
	<brief_summary>The purpose study evaluate efficacy topical tacrolimus different subtypes cutaneous lupus erythematosus . As show several group activate memory T lymphocytes play key role pathogenesis lupus erythematosus . Tacrolimus target T lymphocytes suppresses activation inhibit expression cytokine gene , IL-2 . Therefore , treatment cutaneous lupus erythematosus topical tacrolimus might result improvement skin lesion patient .</brief_summary>
	<brief_title>Efficacy Topical Tacrolimus Different Subtypes With Cutaneous Lupus Erythematosus ( CLE )</brief_title>
	<detailed_description>In patient cutaneous lupus erythematosus ( CLE ) , topical corticosteroid mainstay treatment ; however , long-term use lead numerous side effect include skin atrophy . Recently , topical tacrolimus suggest effective patient different manifestation CLE single additive therapy . Its anti-inflammatory effect explain inhibition calcineurin suppression proinflammatory cytokine interleukins-2 , -3 , -4 , granulocyte colony-stimulating factor , tumour necrosis factor alpha . In study , evaluate efficacy tacrolimus 30 patient different form CLE ( ACLE , SCLE , DLE , LET ) . During period 3 month tacrolimus ointment placebo apply two separate skin lesion . Clinical follow-up examination include photo documentation perform every 4 week .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus , Cutaneous</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Cutaneous lupus erythematosus confirm histological analysis Topical use glucocorticosteroids stop least two week start study Presence two primary skin lesion clinical score â‰¥ 1 Written inform consent available prior screening procedure Systemic medication take lupus erythematosus ( e.g . chloroquine hydroxychloroquine ) start least 6 month prior begin study Women childbearing potential use inadequate birth control measure Pregnancy lactation Known hypersensitivity tacrolimus excipients Patients receive systemic immunosuppressive drug cytotoxic agent antimalarial agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Cutaneous lupus erythematosus</keyword>
	<keyword>Tacrolimus ointment</keyword>
	<keyword>Topical treatment</keyword>
	<keyword>Skin lesion</keyword>
</DOC>